Royalty Pharma vs Zoetis
Royalty Pharma (RPRX) and Zoetis (ZTS) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $39.4B
- Last close
- $68.45
- 12 months
- +78.3%
- Market value
- $32.9B
- Last close
- $79.11
- 12 months
- −31.7%
At a glance
- The biggest part of Zoetis's revenue is Vaccines, 21% of the total in its last annual report.
- Royalty Pharma and Zoetis are close in size by market value ($39.4B and $32.9B).
- Over the last 12 months Royalty Pharma's share price moved +78.3% and Zoetis's −31.7%; against the S&P 500 that is +72.6 points and −37.5 points.
- In their last fiscal years Royalty Pharma kept 32.4% of revenue as net income and Zoetis 28.2%.
- In the last 90 days insiders reported 0 open-market purchases at Royalty Pharma and 0 at Zoetis; members of Congress disclosed 0 trades in Royalty Pharma and 4 in Zoetis.
- Next results: Royalty Pharma Feb 9, 2027, Zoetis Feb 10, 2027.
How each one makes money: Royalty Pharma revenue · Zoetis revenue
Share prices on one chart
Royalty Pharma and Zoetis, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Royalty Pharma RPRXNASDAQ · Pharmaceutical Preparations | Zoetis ZTSNYSE · Pharmaceuticals | |
|---|---|---|
| Size and profitability | ||
| Market value | $39.4B | $32.9B |
| Revenue, last fiscal year | $2.38B | $9.47B |
| Net income, last fiscal year | $771M | $2.67B |
| Net marginNet income as a share of revenue | 32.4% | 28.2% |
| Free cash flow | $2.49B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Zoetis against
Common questions
How is Royalty Pharma different from Zoetis?
Royalty Pharma (RPRX) is in Pharmaceutical Preparations on NASDAQ, with $2.38B of revenue in its last fiscal year and a net margin of 32.4%. Zoetis (ZTS) is in Pharmaceuticals on NYSE, with $9.47B of revenue in its last fiscal year and a net margin of 28.2%. The biggest part of Zoetis's revenue is Vaccines, 21% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Royalty Pharma and Zoetis compare in size?
Royalty Pharma has the larger market value: Royalty Pharma $39.4B and Zoetis $32.9B, at the last close.
Whose share price rose more over the last 12 months, RPRX or ZTS?
Over the last 12 months Royalty Pharma moved +78.3% and Zoetis −31.7%. Past price moves say nothing about the future.
Which has had more insider buying, Royalty Pharma or Zoetis?
Since 2006, Zoetis insiders reported 25 open-market purchases against 18 for Royalty Pharma. These are counts of what was filed, not a view on either stock.
Do members of Congress trade RPRX or ZTS?
In the last 12 months, members of Congress disclosed 0 trades in Royalty Pharma (RPRX) and 14 in Zoetis (ZTS).
When did insiders last buy RPRX and ZTS?
Royalty Pharma: Jun 28, 2023. Zoetis: May 13, 2026.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Royalty Pharma pageZoetis pageRare insider trades this weekAll comparisons
https://oqro.io/compare/rprx-vs-zts







